Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
" And our recent clinical trial was life changing for some patients "
A pretty amazing result for any drug trial, which presumably ensures its continued development and subsequent funding which potentially could add significant value, news of which could arrive at anytime.
As far as funding news for the potential Covid-19 trial for SFX-01, i'm sure most were hoping for news by now, although its perceived delay could be connected to the appointment of a new CEO, whereby they want the new leader in place before news on funding is released which would make perfect sense, rather than the other way around, and so hopefully not too much longer before all is made clear. Gla ;-)
News on progress and potential JV partnership/funding on SFX-01 for Breast Cancer highly likely, with study results published 30/5/20 in ‘Oncogene’ publication, linked to the scientific journal Nature.
.........................
2/6/20
Drug developed to fight breast cancer uses compound found in broccoli
htTps://www.macaubusiness.com/portugal-drug-developed-to-fight-breast-cancer-uses-compound-found-in-broccoli/
..........
Article
30 May 2020 Open Access
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancerBruno M. Simões, Angélica Santiago-Gómez[…]Robert B. Clarke
hTtps://www.nature.com/onc/
..................
Evgen Investor Presentation - January 2020 which outlines next steps for development.
SFX-01 prevents tumour metastases by targeting STAT3
SFX-01 can be life-changing
STEM showed that SFX-01 shrinks tumoursand halts tumour growth
.........
What is the opportunity ?
ER+ breast cancer is the most prevalent breast cancer sub-type (70%)
Metastatic breast cancer is incurable with 5-year survival rates of 22%
Patients become resistant to all drugs
SFX-01 is being developed to prevent and/or reverse resistance
Our data on SFX-01 shows prevention of metastases by the STAT3 pathway
And our recent clinical trial was life changing for some patients
.............
Market opportunityin ER+ metastatic breast cancer
Incidence of ER+ metastatic breast cancer is approximately 130,0001in US and Europe
CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy
Pfizer (Ibrance®/palbociclib), Novartis (Kisqali®/ribociclib) and Eli Lilly (Versenio®/abemaciclib ) are the key players with billion plus sales - sales forecast to reach c.$9bn by 2021
All patients become resistant to CDK4/6 inhibitors
Treatment options post CDK4/6 inhibitors are generally poorly tolerated – treatments which improve quality of life are needed in this terminal populationPotential of SFX-01 to be treatment of choice post CDK4/6 inhibitor failure, extending progression free survival with favourable side-effect profile
Next Steps
Start the path to registration with an adaptive Phase IIb/III study – trial design to be developed in H1 2020
All preclinical breast data due to published in high impact journal early in 2020
Supplementary preclinical work to cement the right opportunity will commence early 2020
New “commercial ready” solid tablet formulation completed in H2 2020
Early partnering or sourcing of non-dilutive capital to fund the IIb part of the study in H2 2020
CTA/IND by end of 2020
Targeting first patient first dose H1 2021
http://evgen.com/wp-content/uploads/2020/01/EVG-Investor-Presentation-13Jan20-FINAL-.pdf
Another 250k buy!!! All bodes well ;-)
Fingers crossed funding news is leaking. Gla :-)
A 250k buy just in....Gla :-)
0 0 0
MNA International
2nd June 2020
Portugal: Drug developed to fight breast cancer uses compound found in broccoli
A new drug based on a natural compound found in broccoli, brussels sprouts and other vegetables may be effective in reversing or even preventing resistance to breast cancer hormone therapy, according to a scientific report.
Portuguese scientist Bruno Simões and other scientists at the University of Manchester, UK, have discovered that the drug SFX-01 may reverse or even prevent resistance to treatment by blocking a major cancer signalling route called STAT3.
The drug was developed with a British company that stabilised the sulforaphane compound, which US researchers had already shown to affect cancer treatment, and which Bruno Simões and his colleagues tested on mice to ensure that the stabilised molecule had the same impact.
A clinical test was then carried out on more than 40 patients, which concluded that 25% saw their cancer stop progressing during the six months they received treatment.
“Many of these cancers eventually develop resistance to treatment. What we have shown is that this compound can eliminate cells that are resistant to treatment,” he told Lusa.
The result of the study was published on Saturday in the ‘Oncogene’ publication, linked to the scientific journal Nature, and represents, according to Simoes, an example of translational research, which started from a basic investigation of the biological mechanism and had a real application, being now in clinical trials.
This drug will continue to be developed with more clinical tests to test efficacy, but Bruno Simões, who graduated from the Faculty of Sciences in Lisbon and completed his PhD in Bilbao, Spain, intends to focus on research into prevention mechanisms.
“When breast cancer reaches an advanced stage, no matter how many drugs we try to use, we can only slow down the progression a little, but it is difficult to control it. We are interested in studying cases of high-risk women to identify drugs that can prevent cancer from occurring,” he said.
htTps://www.macaubusiness.com/portugal-drug-developed-to-fight-breast-cancer-uses-compound-found-in-broccoli/
..........
Article
30 May 2020 | Open Access
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancerBruno M. Simões, Angélica Santiago-Gómez[…]Robert B. Clarke
hTtps://www.nature.com/onc/